Brief: Bachem H1 EBITDA Down At CHF 67.3 Mln

BACHEM HOLDING AG

25/08/2022 06:20

Aug 25 (Reuters) - BACHEM HOLDING AG  BANB.S :
    * H1 EBITDA IS CHF 67.3 MILLION (-10.8% COMPARED TO THE SAME
PERIOD LAST YEAR) WITH A MARGIN OF 28.7%.
    * H1 EBIT OF CHF 51.6 MILLION (-16.8% COMPARED TO THE SAME
PERIOD
LAST YEAR) WITH A MARGIN OF 22.0%
    * FOR THE FULL YEAR 2022, BACHEM EXPECTS GROWTH IN GROUP
SALES IN
THE MID- TO HIGH-SINGLE DIGIT
    * FOR THE FIVE-YEAR PERIOD 2022-2026, BACHEM CONTINUES TO
EXPECT
ANNUAL SALES GROWTH OF 15% ON AVERAGE
    * FOR THE FIVE-YEAR PERIOD 2022-2026, BACHEM SEES EBITDA
MARGIN OF
MORE THAN 30%
    * H1 RECORDED SALES OF CHF 234.9 MILLION (-1.8% COMPARED TO
THE
SAME PERIOD OF THE PREVIOUS YEAR)
    * GOAL OF CHF 100 MILLION IN SALES FROM THE OLIGONUCLEOTIDE
BUSINESS SHOULD BE ACHIEVED IN 2023
    * H1 NET INCOME OF CHF 36.6 MILLION (-31.1%) WITH A MARGIN
OF
15.6% (FIRST HALF OF 2021: 22.2%)

Further company coverage:  BANB.S 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))